Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 3Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 1780Neoplasms 1500Carcinoma, Non-Small-Cell Lung 1045Prostatic Neoplasms 958Colorectal Neoplasms 882Lung Neoplasms 803Pancreatic Neoplasms 573Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 541Stomach Neoplasms 513Ovarian Neoplasms 508Neoplasm Metastasis 499Multiple Myeloma 494Recurrence 412Melanoma 387Squamous Cell Carcinoma of Head and Neck 370Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 356Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 306Endometrial Neoplasms 305Triple Negative Breast Neoplasms 299Glioblastoma 299Rectal Neoplasms 282Sarcoma 266Urinary Bladder Neoplasms 264Hematologic Neoplasms 264Colonic Neoplasms 255

Interventions

relatlimab 1pembrolizumab 1enfortumab vedotin 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Cystoscopy 1Cisplatin 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Muscle Invasive Bladder Urothelial Carcinoma × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Hoosier Cancer Research Network

Phase 2 Recruiting
47 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT06257017 2025-04-04

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

The University of Hong Kong

Phase 2 Recruiting
20 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡